Wellington Management Discloses 6.02% Stake in Celldex Therapeutics

TL;DR

**Wellington Management still owns 6.02% of Celldex, a slight reduction but still a big vote of confidence.**

AI Summary

Wellington Management Group LLP, a major investment firm, filed an amended SC 13G/A on February 8, 2024, disclosing its ownership in Celldex Therapeutics, Inc. (NASDAQ: CLDX). As of December 29, 2023, Wellington reported beneficial ownership of 10,022,933 shares of Celldex's common stock, representing 6.02% of the company. This is an update to their previous holdings, indicating a significant, though slightly reduced, stake in the biotech firm, which is important for investors as it shows a large institutional investor's continued, albeit adjusted, confidence in Celldex.

Why It Matters

This filing shows that a major institutional investor, Wellington Management, continues to hold a substantial position in Celldex, signaling their ongoing interest in the company's future, which can influence other investors' perceptions.

Risk Assessment

Risk Level: low — This filing is a routine update from a large institutional investor and does not indicate any immediate negative or highly volatile event for the stock.

Analyst Insight

Investors should note that a major institutional investor like Wellington Management Group LLP continues to hold a substantial stake in Celldex Therapeutics, Inc., which could be seen as a vote of confidence, but also understand that institutional holdings can change, so monitoring future filings is advisable.

Key Numbers

• 10,022,933 — Shares Beneficially Owned (Represents Wellington Management Group LLP's total holdings in Celldex Therapeutics, Inc. as of December 29, 2023.)
• 6.02% — Percentage of Class (Indicates the proportion of Celldex Therapeutics, Inc.'s common stock owned by Wellington Management Group LLP, showing a significant institutional stake.)

Key Players & Entities

• Wellington Management Group LLP (company) — the investment firm filing the SC 13G/A
• Celldex Therapeutics, Inc. (company) — the subject company whose shares are being reported
• 10,022,933 (dollar_amount) — number of shares beneficially owned by Wellington Management
• 6.02% (dollar_amount) — percentage of Celldex's common stock beneficially owned by Wellington Management
• December 29, 2023 (date) — the date of the event requiring the filing
• February 8, 2024 (date) — the filing date of the SC 13G/A amendment

Forward-Looking Statements

• Wellington Management Group LLP will maintain a significant, though potentially fluctuating, stake in Celldex Therapeutics, Inc. for the foreseeable future. (Wellington Management Group LLP) — medium confidence, target: December 29, 2024

FAQ

Filing Documents

• SEC13G_Filing.htm (SC 13G/A) — 35KB
• 0000902219-24-000057.txt ( ) — 37KB

From the Filing

SC 13G/A 1 SEC13G_Filing.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 ) * Celldex Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 15117B202 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes.) CUSIP No. 15117B202 1. NAMES OF REPORTING PERSONS Wellington Management Group LLP 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [ ] 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Massachusetts NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 6,108,315 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 6,476,561 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 6,476,561 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 11.84% 12. TYPE OF REPORTING PERSON HC CUSIP No. 15117B202 1. NAMES OF REPORTING PERSONS Wellington Group Holdings LLP 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [ ] 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 6,108,315 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 6,476,561 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 6,476,561 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 11.84% 12. TYPE OF REPORTING PERSON HC CUSIP No. 15117B202 1. NAMES OF REPORTING PERSONS Wellington Investment Advisors Holdings LLP 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [ ] 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 6,108,315 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 6,476,561 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 6,476,561 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 11.84% 12. TYPE OF REPORTING PERSON HC CUSIP No. 15117B202 1. NAMES OF REPORTING PERSONS Wellington Management Company LLP 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [ ] 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 6,077,974 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 6,311,549 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 6,311,549 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 11.54% 12. TYPE OF REPORTING PERSON IA Item 1. (a) Name of Issuer Celldex Therapeutics, Inc. (b) Address of Issuer's Principal Executive Offices 53 Frontage Road Suite 220 Hampton, NJ 08827 Item 2. (a) Name of Person Filing Wellington Management Group LLP Wellington Group Holdings LLP Wellington Investment Advisors Holdings LLP Wellington Management Company LLP (b) Address of Principal Business Office or, if None, Residence c/o Wellington Management Company LLP 280 Congress Street Boston, MA 02210 (c) Citizenship Wellington Management Group LLP - Massachusetts Wellington Group Holdings LLP - Delaware Wellington Investment Advisors Holdings LLP - Delaware Wellington Management Company LLP - Delaware (d) Title of Class of Securities Common Stock (e) CUSIP Number 15117B202 Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a: (a) [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o). (b) [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c). (c) [ ] Insurance Company as

View Full Filing

View this SC 13G/A filing on SEC EDGAR